Prescribing patterns and adherence to medication among South-Asian, Chinese and white people with Type 2 diabetes mellitus: A population-based cohort study

Diabetic Medicine

Volumn 31, Issue 12, 2014, Pages 1586-1593

  Chong, E ^a   Wang, H ^b   King Shier, K M ^c   Quan, H ^d   Rabi, D M ^d   Khan, N A ^b,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Center for Health Evaluation and Outcome Sciences   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIGUANIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANADA; CAUCASIAN; CHINESE; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRESCRIPTION; PREVALENCE; SOUTH ASIAN; TREATMENT OUTCOME; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLINICAL PRACTICE; DIABETES MELLITUS, TYPE 2; ETHNOLOGY; FEMALE; MALE; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIA, WESTERN; ASIAN CONTINENTAL ANCESTRY GROUP; BRITISH COLUMBIA; CHINA; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SOCIAL CLASS;

EID: 84910655216     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12559     Document Type: Article

References (41)

1. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis in Ontario, Canada 1996/97. Diabetes Care 2004; 27: 407-414.
2. Nichols GA, Gullion CM, Koro C, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes. An update. Diabetes Care 2004; 27: 1879-1884.
3. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K et al. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 2005; 28: 355-359.
4. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 1998; 21: 1138-1145.
5. Forouhi NG, Sattar N, Tillin T, McKeigue PM, Chaturvedi N. Do known risk factors explain the higher coronary heart disease mortality in South Asian compared with European men? Prospective follow-up of the Southall and Brent studies. UK. Diabetologia 2006; 49: 2580-2588.
6. Teo KK, Liu L, Chow CK, Wang X, Islam S, Jiang L et al. INTERHEART Investigators in China. Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study. Heart 2009; 95: 1857-1864.
7. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080.
8. Brenner B, Cooper M, De Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
9. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
10. Bhattacharyya OK, Estey EA, Cheng AY, Canadian Diabetes Association. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009; 55: 39-43.
11. Negandhi PH, Ghouri N, Colhoun HM, Fischbacher CM, Lindsay RS, McKnight JA et al. Ethnic differences in glycaemic control in people with type 2 diabetes mellitus living in Scotland. PLoS One 2013; 8: e83292.
12. Gray J, Millett C, Saxena S, Netuveli G, Khunti K, Majeed A. Ethnicity and quality of diabetes care in a health system with universal coverage: population-based cross-sectional survey in primary care. J Gen Intern Med 2007; 22: 1317-1320.
13. Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrbach JL, Jiang H et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1689-1694.
14. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332: 1177-1181.
15. Lopez-Quintero C, Berry EM, Neumark Y. Limited English proficiency is a barrier to receipt of advice about physical activity and diet among Hispanics with chronic diseases in the United States. J Am Diet Assoc 2009; 109: 1769-1774.
16. King KM, Mather CD, Sanguins J. Ethnocultural affiliation, gender, and cardiovascular disease risk management. Can J Cardiovasc Nurs 2005; 15: 10-16.
17. Pieroni A, Sheikh QZ, Ali W, Torry B. Traditional medicines used by Pakistani migrants from Mirpur living in Bradford. Northern England. Complement Ther Med 2008; 16: 81-86.
18. Chen G, Khan N, Walker R, Quan H. Validating a coding algorithm for diabetes mellitus using administrative data. Diabetes Res Clin Pract 2010; 89: 189-195.
19. Nam Pehchan News, Summer 1998. Bradford: Computer Services, Bradford Council (Dept 13).
20. Quan H, Wang F, Schopflocher D, Norris C, Norris C, Galbraith PD et al. Development and validation of a surname list to define Chinese ethnicity. Med Care 2006; 44: 328-333.
21. Cummins C, Winter H, Cheng KK, Maric R, Silcocks P, Varghese C. An assessment of the Nam Pehchan computer program for the identification of names of south Asian ethnic origin. J Public Health Med 1999; 21: 401-406.
22. Harding S, Dews H, Simpson SL. The potential to identify South Asians using a computerized algorithm to classify names. Popul Trends 1999; 97: 46-49.
23. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574.
24. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-1288.
25. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005; 11: 449-457.
26. Caetano PA, Lam JMC, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 2006; 28: 1411-1424.
27. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008; 46: 1125-1133.
28. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measure using administrative claims data. Curr Med Res Opin 2009; 25: 2303-2310.
29. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012; 125: e1-7.
30. Gholap N, Davies M, Patel K, Sattar N, Khunti K. Type 2 diabetes and cardiovascular disease in South Asians. Prim Care Diabetes 2011; 5: 45-56.
31. Morgan S, Hanley G, Cunningham C, Quan H. Ethnic differences in the use of prescription drugs: a cross-sectional analysis of linked administrative data. Open Med 2011; 5: e87-93.
32. Lai EJ, Grubisic M, Palepu A, Quan H, King KM, Khan NA. Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients [published online Sept 18, 2011]. BMC Cardiovasc Disord 2011; 11: 56.
33. Gee ME, Janssen I, Pickett W, Pickett W, McAllister FA, Bancej CM et al. Prevalence, awareness, treatment, and control of hypertension among Canadian adults with diabetes, 2007 to 2009. Can J Cardiol 2012; 28: 367-374.
34. Wong MC, Kong AP, So WY, Jiang JY, Chan JC, Griffiths SM. Adherence to oral hypoglycemic agents in 26, 782 Chinese patients: a cohort study. J Clin Pharmacol 2011; 51: 1474-1482.
35. Li WW, Wallhagen MI, Froelicher ES. Hypertension control, predictors for medication adherence and gender differences in older Chinese immigrants. J Adv Nurs 2007; 61: 326-335.
36. Lee GKY, Wang HHX, Liu KQL, Cheung Y, Morisky DE, Wong MC. Determinants of medication adherence to antihypertensive medications among a Chinese population using Morisky Medication Adherence scale. PLoS One 2013; 8: e62775.
37. Li WW, Froelicher ES. Gender differences in Chinese immigrants: predictors for antihypertensive medication adherence. J Transcult Nurs 2007; 18: 331-338.
38. Wilson E, Wardle EV, Chandel P, Walford S. Diabetes education: an Asian perspective. Diabet Med 1993; 10: 177-180.
39. Li WW, Stotts NA, Froelicher ES. Compliance with antihypertensive medication in Chinese immigrants: cultural specific issues and theoretical application. Res Theory Nurs Pract 2007; 21: 236-254.
40. Health Canada safety information for rosuvastatin (Crestor). Available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/13453a-eng.php. Last accessed 1 April 2014.
41. Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-850.